Paul Arthur LaViolette
Independent DirectorMr. Paul Arthur LaViolette, M.B.A. is Member of Advisory Board of Carvolix SA from April 2026. He is Director of Vibrato Medical, Inc. Mr. LaViolette is President, Chief Executive Officer, at Pulse Biosciences, Inc. since January 9, 2025 and was its Independent Co-Chairman of the Board since August 2024 until January, 2025 and is its Co-Chairman of the Board from January, 2025 and serves as its Director since August 9, 2024. Mr. LaViolette has significant experience as a large-scale operator at global healthcare corporations as well as a leader to a diverse group of innovative medical technology startups as a venture investor and board member. Mr. LaViolette is a director for Edwards Lifesciences and Chairman of the Innovation Advisory Board at Mass General Brigham. Mr. LaViolette serves as Independent Director of Edwards Lifesciences Corporation since July 2020. Mr. LaViolette served as an Independent Director at Misonix, Inc. since September 27, 2019 and its Independent Chairman of the Board since October 1, 2019 until 2021. He serves as a Director of SpectraWAVE, Inc. He has been Director of Solsys Medical, LLC (formerly known as Soluble Systems, LLC), since February 2018. He serves on the Board of Directors of several early and growth stage private medical device companies. Mr. LaViolette serves as Director of Bardy Diagnostics, Inc. He serves as Managing Partner of SV Health Investors, LLC since 2025. Mr. LaViolette has been Managing Partner and the Chief Operating Officer at SV Health Investors, LLC since January 13, 2014 till 2025. He is responsible for the investment of SV’s Medtech Convergence Fund. He is a Director of Stimwave LLC since August 23, 2018. He serves as Managing Partner and Chief Operating Officer at Medtech Convergence Fund at SV Health Investors. He served as a General Partner from January 2011 to December 2013. Mr. LaViolette joined SV Health Investors, LLC in 2009 and served as a Venture Partner from 2009 to December 2010. He has significant experience of global medical technology management experience. Mr. LaViolette serves as an Advisor to Aleva Neurotherapeutics. He focuses on medical devices. He served as the Chief Operating Officer at Boston Scientific Corporation from December 20, 2004 to June 2008 and held global responsibilities for all its business units except Cardiac Rhythm Management. During his tenure, company grew revenue. He joined Boston Scientific Corp. as the President of Boston Scientific International and Vice President of International in January 1994. Mr. LaViolette served as Group President of Cardiovascular at Boston Scientific Corp. He served as a Senior Vice President and Group President of Nonvascular Businesses at Boston Scientific Corp. since February 1995. Mr. LaViolette served as the President of Boston Scientific International since October 1998 and assumed responsibility for Boston Scientific Corp.'s Scimed, EPT and Target businesses as Group President of Cardiovascular in February 2000. He served as the President of EP Technologies, Inc. since 2000. Prior to joining SV Health Investors, Mr. LaViolette spent nearly three decades building and leading medical device businesses. From 1994 to 2008, Mr. LaViolette served in several roles at Boston Scientific Corporation including President of Cardiology and International, Group President of Cardiovascular and Endosurgery and Chief Operating Officer. Mr. LaViolette served as the President of SCIMED since March 2001 and was responsible for the Interventional Cardiology, Peripheral Interventions, Vascular Surgery, Electrophysiology and Neurovascular businesses. During his tenure at BSC, he served as COO, Group President, Cardiovascular, Group President, EndoSurgery, President-Cardiology and President-International. Mr. LaViolette previously held marketing and general management positions at CR Bard and various marketing roles at Kendall (Covidien). He was also responsible for Boston Scientific International, Corporate Sales and National Accounts, Healthcare Strategies and Programs and Government Affairs. He spent quiet a long period at C.R. Bard, Inc. and at Kendall (Medtronic) from 1980 to 1984. Mr. LaViolette was employed by C.R. Bard, Inc. from 1984 to 1993 in various capacities, including President, U.S.C.I. Division, from July 1993 to November 1993, President of U.S.C.I. Angioplasty Division from January 1993 to July 1993, Vice President and General Manager of U.S.C.I. Angioplasty Division from August 1991 to January 1993, President of the Cardiology Division and Vice President of U.S.C.I. Division from January 1990 to August 1991. Previously, he held several marketing positions at C.R. Bard, including Vice President of Marketing for USCI. Mr. LaViolette served with the Kendall Company's Hospital Products Division. He served as an Executive at CR Bard Inc. and Kendall International, Inc. Mr. LaViolette has been the Chairman of the Board at TransEnterix, Inc since September 2013. He serves as Chairman at Corvia Medical, Inc. (formerly DC Devices Inc.). He had been the Chairman of the Board of Ximedica, LLC since November 2014 until 2020. He has been Executive Chairman of CardioFocus, Inc. since April 2013. He serves as the Chairman of Stimwave Technologies, Inc. and served as its Interim Chief Executive Officer since 2019. He served as the Chairman of Direct Flow Medical, Inc. where has been on Board since September 2008. He served as the Chairman at Baxano Surgical, Inc. (formerly TranS1, Inc.) since May 2012, TranS1, Inc. since August 2008 and its Lead Director from January 04, 2011 to May 2012. He integrated two dozen acquisitions and led extensive product development, manufacturing and worldwide commercial organizations. Previously, he held marketing and general management positions at CR Bard and various marketing roles at Kendall. He has been Director of CSA Medical, Inc. since December 15, 2011. He serves as a Director of CardioKinetix, Inc., Coridea NC2, Trans 1 ValenTx; CardioFocus, Inc., Axon Therapies Inc. and ValenTx. He serves as the Chairman of Endotronix Inc. He had been a Director at Asensus Surgical, Inc. (formerly known as TransEnterix, Inc.) since 2013 and served as its Chairman since September 2013 until October 2021. He served as a Director of Thoratec Corp. from May 2009 to October 8, 2015. He served as a Director of DJO Opco Holdings, Inc. since January 2009. He served as a Director of Conceptus, Inc. from December 2008 to June 5, 2013; He served on the boards of Percutaneous Valve Technologies, Inc., Cameron Health, Urologix, Inc., AdvaMed (Advanced Medical Technology Association) and the New England Health Care Institute. He served as Director of DJO Global, Inc. and DJO Finance LLC from January 2009 to June 29, 2012. He serves as the Chairman of the Board Medical Device Manufacturers Association. Mr. LaViolette has served as a Director of the Medical Device Manufacturers Association. He served as a Vice Chairman of the Innovation Advisor
Positions
- Company NameEdwards Lifesciences CorporationStock CodeEWPositionIndependent DirectorColleagues
- BJBernard J. ZovighianCEO & Director
- NJNicholas J. ValerianiIndependent Chairman
- DEDonald E. BoboCorporate Vice President of Strategy & Corporate Development
- DCDaveen ChopraCorporate Vice President of Transcatheter Mitral & Tricuspid Therapies
- AMAnnette Maria BrulsCorporate Vice President of EMEA, Canada, & Latin America
- TMTheodora MistrasCorporate VP & CFO
- LSLeslie Stone HeiszIndependent Director
- KTKieran T. GallahueIndependent Director
- Company NamePulse Biosciences, Inc.Stock CodePLSEPositionPresident, CEO & Co-Chairman of the BoardColleagues
- PAPaul Arthur LaViolettePresident, CEO & Co-Chairman of the Board
- RWRobert W. DugganIndependent Co-Chairman
- JSJon SkinnerChief Financial Officer
- DRDarrin R. UeckerCTO & Director
- LTLiane TeplitskyChief Operating Officer
- STSteven T. WeberVP of Accounting, Principal Accounting Officer & Global Corporate Controller
- MSManmeet Singh SoniLead Independent Director
- MZMahkam ZanganehIndependent Director
